Insmed Inc (INSM) 17.40 $INSM
17 Healthcare Companies To Consider Based On Patent Dynamics And IP/Patent Indexes
Innovalpha - Seeking Alpha - Tue Feb 10, 8:08AM CST
Introduction We will present here a few healthcare stocks that have been recently selected by our IP models. As already explained in our SA article " Patent Dynamics And Stock Performance ", Innovalpha has developed proprietary IP and...
SGYP: 2.98 (unch), INSM: 17.40 (+0.69), RNN: 0.75 (+0.01), ZSPH: 46.77 (+3.42), RDHL: 12.69 (+0.04), ASPX: 65.76 (+2.76), ACUR: 0.55 (+0.01), XNPT: 6.69 (-0.21), SPNC: 33.69 (-0.06), CORI: 7.00 (-0.05), SAGE: 41.03 (-0.07), EBIO: 10.13 (+0.05), HAE: 42.94 (-0.59), JAZZ: 169.69 (+6.89), ICPT: 209.12 (+7.12), NVDQ: 15.12 (+0.51)
Insmed to Participate at February Investment Conferences
Business Wire - Wed Jan 28, 7:00AM CST
Insmed Incorporated (Nasdaq:INSM) today announced that Company management will participate at the following investor conferences in February:
INSM: 17.40 (+0.69)
Insmed Incorporated announces stock option awards to two new employees pursuant to NASDAQ Listing Rule 5635(c)(4)
M2 - Wed Jan 14, 6:59AM CST
Biopharmaceutical company Insmed (NasdaqGS:INSM) announced on Tuesday that it has awarded non-statutory stock options to purchase an aggregate of 100,000 common shares to two new employees.
INSM: 17.40 (+0.69)
Insmed Incorporated Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Business Wire - Tue Jan 13, 7:01AM CST
Insmed Incorporated (NASDAQ:INSM) today announced that on January 8, 2015, it approved non-statutory stock options to purchase an aggregate of 100,000 shares of its common stock to two new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of these new hires' employment compensation in connection with the Company's equity grant program.
INSM: 17.40 (+0.69)
Insmed to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Business Wire - Tue Jan 06, 7:30AM CST
Insmed Incorporated (Nasdaq:INSM) today announced that Company management will participate at the 33rd Annual J.P. Morgan Healthcare Conference taking place from January 12-15, 2015 in San Francisco. Will Lewis, President and CEO of Insmed, will deliver a corporate presentation on Wednesday, January 14th at 9:00 a.m. PST.
INSM: 17.40 (+0.69), JPM: 59.67 (+0.10)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), FPRX: 24.63 (+0.63), ZFGN: 39.06 (+0.92), CRIS: 3.23 (+0.25), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Insmed Appoints Myrtle Potter to its Board of Directors
Business Wire - Mon Dec 15, 7:01AM CST
Insmed Incorporated (Nasdaq:INSM) today announced the appointment of Myrtle Potter to its Board of Directors. Ms. Potter is currently CEO of Myrtle Potter & Company, a life sciences and healthcare advisory firm she founded in 2005. She was previously the President of Commercial Operations and Chief Operating Officer of Genentech and had extensive experience in senior operating roles at Bristol-Myers Squibb and Merck.
INSM: 17.40 (+0.69)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), ZGNX: 1.43 (+0.05), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), NDAQ: 49.48 (-0.27), FPRX: 24.63 (+0.63), CRIS: 3.23 (+0.25), ZFGN: 39.06 (+0.92), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Insmed Provides End of Year Regulatory and Clinical Update
Business Wire - Mon Dec 15, 6:00AM CST
Insmed Incorporated (Nasdaq:INSM) today provides a regulatory and clinical update on the Company's development programs.
INSM: 17.40 (+0.69)
Critical Alerts For Twitter, Insmed, Spansion, Advanced Micro Devices and BlackBerry Released By InvestorsObserver
PR Newswire - Wed Dec 03, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for TWTR, INSM, CODE, AMD and BBRY.
INSM: 17.40 (+0.69), AMD: 3.15 (+0.03), BBRY: 10.09 (+0.23), TWTR: 48.50 (+0.55), CODE: 35.99 (+0.03)
Nasdaq stocks posting largest percentage increases
AP - Tue Dec 02, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
INSM: 17.40 (+0.69), CY: 14.76 (+0.01), SSRI: 6.26 (+0.13), ORPN: 7.17 (+0.04), OTIC: 31.14 (+0.13), DMRC: 28.66 (+0.98), AVNR: 16.96 (unch), SSO.TO: 7.81 (+0.16), PAA.TO: 14.78 (+0.20), PAAS: 11.85 (+0.18), AMIC: 10.75 (-0.10), RGLD: 71.46 (+0.50), MTEX: 23.89 (+0.69), DGLY: 11.50 (-0.40)
Insmed to Participate at December Investment Conferences
Business Wire - Wed Nov 26, 7:30AM CST
Insmed Incorporated (Nasdaq:INSM) today announced that Company management will participate at the following investor conferences in December:
INSM: 17.40 (+0.69)
Insmed Earnings Hindsight: Down 4.8% in Last 18 Days (INSM)
Comtex SmarTrend(R) - Mon Nov 24, 9:07AM CST
18 days ago, on November 6th, 2014, Insmed (NASDAQ:INSM) reported its earnings. Analysts, on average, expected a loss of $0.45 per share on sales of $0.0 thousand. Insmed actually reported a loss of $0.54 per share on sales of $0.0 thousand, missing EPS estimates by $0.09 and matching revenue estimates. Since the company's report, shares of Insmed have fallen from $14.20 to $13.52, representing a loss of 4.8% in the past 18 days.
INSM: 17.40 (+0.69)
Update: Insmed Q3 2014 Earnings
Andy Batts - at Seeking Alpha - Tue Nov 18, 7:50AM CST
INSM: 17.40 (+0.69)
Insmed Earnings Review: 11 Days after Announcement Shares Down 7.0% (INSM)
Comtex SmarTrend(R) - Mon Nov 17, 1:32PM CST
When Insmed (NASDAQ:INSM) reported earnings 11 days ago on November 6th, 2014, analysts, on average, expected the company to report a loss of $0.45 on sales of $0.0 thousand. The company actually reported a loss of $0.54 per share on sales of $0.0 thousand, missing EPS estimates by $0.09 and matching revenue estimates. Shares of Insmed have slipped from $14.20 to $13.21, representing a loss of 7.0%, since the company reported earnings 11 days ago.
INSM: 17.40 (+0.69)
Global Retinopathy Of Prematurity Therapeutics Pipeline Review, H2 2014 - Analysis of 6 Companies & 8 Drug Profiles
M2 - Tue Nov 11, 6:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/tdsmfd/retinopathy_of) has announced the addition of the "Retinopathy Of Prematurity - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Retinopathy Of Prematurity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinopathy Of Prematurity and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Insmed Incorporated - Acucela Inc. - Gene Signal International SA - EyeGene, Inc. - Biomar Microbial Technologies Drug Profiles - mecasermin rinfabate - ranibizumab - aganirsen - Small Molecule for Retinopathy Of Prematurity - emixustat hydrochloride - EG-Mirotin - IB-09A0133 - R-200 For more information visit http://www.researchandmarkets.com/research/td...nopathy_of
INSM: 17.40 (+0.69)
Insmed's (INSM) CEO Bill Lewis on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sat Nov 08, 1:39PM CST
INSM: 17.40 (+0.69)
Insmed posts 3Q loss
Automated Insights - Thu Nov 06, 9:06AM CST
BRIDGEWATER, N.J. (AP) _ Insmed Inc. (INSM) on Thursday reported a loss of $24 million, or 54 cents per share, in its third quarter.
INSM: 17.40 (+0.69)
Insmed (INSM) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Nov 06, 7:25AM CST
INSM: 17.40 (+0.69)
Insmed misses by $0.08
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 6:53AM CST
INSM: 17.40 (+0.69)
17 Healthcare Companies To Consider Based On Patent Dynamics And IP/Patent Indexes
Innovalpha - Seeking Alpha - Tue Feb 10, 8:08AM CST
Introduction We will present here a few healthcare stocks that have been recently selected by our IP models. As already explained in our SA article " Patent Dynamics And Stock Performance ", Innovalpha has developed proprietary IP and...
SGYP: 2.98 (unch), INSM: 17.40 (+0.69), RNN: 0.75 (+0.01), ZSPH: 46.77 (+3.42), RDHL: 12.69 (+0.04), ASPX: 65.76 (+2.76), ACUR: 0.55 (+0.01), XNPT: 6.69 (-0.21), SPNC: 33.69 (-0.06), CORI: 7.00 (-0.05), SAGE: 41.03 (-0.07), EBIO: 10.13 (+0.05), HAE: 42.94 (-0.59), JAZZ: 169.69 (+6.89), ICPT: 209.12 (+7.12), NVDQ: 15.12 (+0.51)
Insmed to Participate at February Investment Conferences
Business Wire - Wed Jan 28, 7:00AM CST
Insmed Incorporated (Nasdaq:INSM) today announced that Company management will participate at the following investor conferences in February:
INSM: 17.40 (+0.69)
Insmed Incorporated announces stock option awards to two new employees pursuant to NASDAQ Listing Rule 5635(c)(4)
M2 - Wed Jan 14, 6:59AM CST
Biopharmaceutical company Insmed (NasdaqGS:INSM) announced on Tuesday that it has awarded non-statutory stock options to purchase an aggregate of 100,000 common shares to two new employees.
INSM: 17.40 (+0.69)
Insmed Incorporated Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Business Wire - Tue Jan 13, 7:01AM CST
Insmed Incorporated (NASDAQ:INSM) today announced that on January 8, 2015, it approved non-statutory stock options to purchase an aggregate of 100,000 shares of its common stock to two new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of these new hires' employment compensation in connection with the Company's equity grant program.
INSM: 17.40 (+0.69)
Insmed to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Business Wire - Tue Jan 06, 7:30AM CST
Insmed Incorporated (Nasdaq:INSM) today announced that Company management will participate at the 33rd Annual J.P. Morgan Healthcare Conference taking place from January 12-15, 2015 in San Francisco. Will Lewis, President and CEO of Insmed, will deliver a corporate presentation on Wednesday, January 14th at 9:00 a.m. PST.
INSM: 17.40 (+0.69), JPM: 59.67 (+0.10)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), FPRX: 24.63 (+0.63), ZFGN: 39.06 (+0.92), CRIS: 3.23 (+0.25), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Insmed Appoints Myrtle Potter to its Board of Directors
Business Wire - Mon Dec 15, 7:01AM CST
Insmed Incorporated (Nasdaq:INSM) today announced the appointment of Myrtle Potter to its Board of Directors. Ms. Potter is currently CEO of Myrtle Potter & Company, a life sciences and healthcare advisory firm she founded in 2005. She was previously the President of Commercial Operations and Chief Operating Officer of Genentech and had extensive experience in senior operating roles at Bristol-Myers Squibb and Merck.
INSM: 17.40 (+0.69)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), ZGNX: 1.43 (+0.05), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), NDAQ: 49.48 (-0.27), FPRX: 24.63 (+0.63), CRIS: 3.23 (+0.25), ZFGN: 39.06 (+0.92), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Insmed Provides End of Year Regulatory and Clinical Update
Business Wire - Mon Dec 15, 6:00AM CST
Insmed Incorporated (Nasdaq:INSM) today provides a regulatory and clinical update on the Company's development programs.
INSM: 17.40 (+0.69)
Critical Alerts For Twitter, Insmed, Spansion, Advanced Micro Devices and BlackBerry Released By InvestorsObserver
PR Newswire - Wed Dec 03, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for TWTR, INSM, CODE, AMD and BBRY.
INSM: 17.40 (+0.69), AMD: 3.15 (+0.03), BBRY: 10.09 (+0.23), TWTR: 48.50 (+0.55), CODE: 35.99 (+0.03)
Nasdaq stocks posting largest percentage increases
AP - Tue Dec 02, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
INSM: 17.40 (+0.69), CY: 14.76 (+0.01), SSRI: 6.26 (+0.13), ORPN: 7.17 (+0.04), OTIC: 31.14 (+0.13), DMRC: 28.66 (+0.98), AVNR: 16.96 (unch), SSO.TO: 7.81 (+0.16), PAA.TO: 14.78 (+0.20), PAAS: 11.85 (+0.18), AMIC: 10.75 (-0.10), RGLD: 71.46 (+0.50), MTEX: 23.89 (+0.69), DGLY: 11.50 (-0.40)
Insmed to Participate at December Investment Conferences
Business Wire - Wed Nov 26, 7:30AM CST
Insmed Incorporated (Nasdaq:INSM) today announced that Company management will participate at the following investor conferences in December:
INSM: 17.40 (+0.69)
Insmed Earnings Hindsight: Down 4.8% in Last 18 Days (INSM)
Comtex SmarTrend(R) - Mon Nov 24, 9:07AM CST
18 days ago, on November 6th, 2014, Insmed (NASDAQ:INSM) reported its earnings. Analysts, on average, expected a loss of $0.45 per share on sales of $0.0 thousand. Insmed actually reported a loss of $0.54 per share on sales of $0.0 thousand, missing EPS estimates by $0.09 and matching revenue estimates. Since the company's report, shares of Insmed have fallen from $14.20 to $13.52, representing a loss of 4.8% in the past 18 days.
INSM: 17.40 (+0.69)
Update: Insmed Q3 2014 Earnings
Andy Batts - at Seeking Alpha - Tue Nov 18, 7:50AM CST
INSM: 17.40 (+0.69)
Insmed Earnings Review: 11 Days after Announcement Shares Down 7.0% (INSM)
Comtex SmarTrend(R) - Mon Nov 17, 1:32PM CST
When Insmed (NASDAQ:INSM) reported earnings 11 days ago on November 6th, 2014, analysts, on average, expected the company to report a loss of $0.45 on sales of $0.0 thousand. The company actually reported a loss of $0.54 per share on sales of $0.0 thousand, missing EPS estimates by $0.09 and matching revenue estimates. Shares of Insmed have slipped from $14.20 to $13.21, representing a loss of 7.0%, since the company reported earnings 11 days ago.
INSM: 17.40 (+0.69)
Global Retinopathy Of Prematurity Therapeutics Pipeline Review, H2 2014 - Analysis of 6 Companies & 8 Drug Profiles
M2 - Tue Nov 11, 6:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/tdsmfd/retinopathy_of) has announced the addition of the "Retinopathy Of Prematurity - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Retinopathy Of Prematurity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinopathy Of Prematurity and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Insmed Incorporated - Acucela Inc. - Gene Signal International SA - EyeGene, Inc. - Biomar Microbial Technologies Drug Profiles - mecasermin rinfabate - ranibizumab - aganirsen - Small Molecule for Retinopathy Of Prematurity - emixustat hydrochloride - EG-Mirotin - IB-09A0133 - R-200 For more information visit http://www.researchandmarkets.com/research/td...nopathy_of
INSM: 17.40 (+0.69)
Insmed's (INSM) CEO Bill Lewis on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sat Nov 08, 1:39PM CST
INSM: 17.40 (+0.69)
Insmed posts 3Q loss
Automated Insights - Thu Nov 06, 9:06AM CST
BRIDGEWATER, N.J. (AP) _ Insmed Inc. (INSM) on Thursday reported a loss of $24 million, or 54 cents per share, in its third quarter.
INSM: 17.40 (+0.69)
Insmed (INSM) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Nov 06, 7:25AM CST
INSM: 17.40 (+0.69)
Insmed misses by $0.08
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 6:53AM CST
INSM: 17.40 (+0.69)
